Online citations, reference lists, and bibliographies.
← Back to Search

Phase I/II Study Of GSK2118436, A Selective Inhibitor Of Oncogenic Mutant BRAF Kinase, In Patients With Metastatic Melanoma And Other Solid Tumors.

R. Kefford, H. Arkenau, M. P. Brown, M. Millward, J. R. Infante, G. V. Long, D. Ouellet, M. Curtis, P. F. Lebowitz, G. S. Falchook

Save to my Library
Download PDF
Analyze on Scholarcy
Share